Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Interest & Investment Income (2019 - 2026)

Pliant Therapeutics has reported Interest & Investment Income over the past 8 years, most recently at $1.7 million for Q1 2026.

  • Quarterly Interest & Investment Income fell 51.46% to $1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.6 million through Mar 2026, down 48.96% year-over-year, with the annual reading at $11.4 million for FY2025, 45.86% down from the prior year.
  • Interest & Investment Income was $1.7 million for Q1 2026 at Pliant Therapeutics, down from $2.0 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $6.5 million in Q3 2023 and troughed at $111000.0 in Q1 2022.
  • The 5-year median for Interest & Investment Income is $3.6 million (2025), against an average of $3.7 million.
  • Year-over-year, Interest & Investment Income surged 4276.58% in 2023 and then tumbled 55.59% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at $2.7 million in 2022, then surged by 135.19% to $6.2 million in 2023, then decreased by 29.24% to $4.4 million in 2024, then tumbled by 55.59% to $2.0 million in 2025, then fell by 11.81% to $1.7 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Interest & Investment Income are $1.7 million (Q1 2026), $2.0 million (Q4 2025), and $2.8 million (Q3 2025).